Neuropace (NPCE)

The RNS System is implanted by a specialist physician and includes a neurostimulator, leads placed at or near the seizure focus, a patient remote monitor and related accessories. Unlike open-loop stimulation approaches that deliver therapy on a fixed schedule, NeuroPace’s system is intended to respond to a patient’s own brain signals in real time. This closed-loop design supports personalized therapy and generates long-term data that clinicians can use to understand seizure activity and adjust care.

The company also provides digital tools that support patient management after implantation. These include the Physician Tablet, a Patient Data Management System and the nSight Platform, which help clinicians review device data, monitor trends and make programming decisions. This combination of implantable hardware, software and longitudinal data is central to NeuroPace’s position in the epilepsy care market.

NeuroPace operates in the highly regulated medical device sector, where adoption depends on clinical evidence, physician training, reimbursement, patient selection and hospital purchasing decisions. Its opportunity is tied to the large population of people living with drug-resistant epilepsy and the need for therapies that can reduce seizure burden while preserving brain tissue. For investors, NPCE offers exposure to a specialized neuromodulation company with a differentiated responsive platform.